AMCP 2026 research posters

Prime Therapeutics (Prime) presents studies on CAR T therapies, medical and pharmacy benefit integration, biologics, mental health parity and more
Click on the poster image to view the full-size version.

At Prime Therapeutics (Prime), clinical and health outcomes research is foundational to how the organization provides stronger clinical judgement to health care payers. By evaluating real-world evidence on how therapies are used, where gaps exist and which patients benefit most from additional support, Prime translates its expertise into smarter clinical strategies and less patient navigation friction. This evidence-based approach helps clients make informed decisions, strengthens program design across complex conditions and reinforces Prime’s position as a trusted partner committed to improving access, affordability and health outcomes by guiding patients through the moments in care where clinical insight and care support matter most.  

Prime is presenting its industry-leading insights on a range of health care topics and trends at the Academy of Managed Care Pharmacy (AMCP) annual meeting from April 13–16 in Nashville, Tenn. AMCP is the nation’s leading professional association that aims to help patients get the medications they need at a cost they can afford. This event annually attracts thousands of industry leaders, health care professionals and stakeholders committed to advancing the field.  

Real-World Treatment-Adherent 3-Year Cost Impact Assessment of Glucagon-Like Peptide-1 Agonists to Treat Obesity Among Commercially Insured Members Without Diabetes

This study earned a gold award from AMCP. It examines how medical and overall health care costs changed over three years for people who stayed on glucagon-like peptide-1 (GLP‑1) receptor agonist medications for obesity when compared to a matched control group.

Real-World 3-Year Cost Impact Assessment of Glucagon-Like Peptide-1 Agonists to Treat Obesity Among Commercially Insured Members without Diabetes

This study earned a silver award from AMCP.  It assesses real‑world changes in annual medical spending and total cost of care at three years for commercially insured individuals without diabetes who started GLP‑1 therapy for obesity compared to a matched control group. 

The Value of Pharmacy Benefit Integration: A Retrospective Comparison of Health Care Costs and Utilization, 2022-2023 

This study earned a silver award from AMCP.  It seeks to compare medical costs and health care resource use between people whose pharmacy benefits are integrated into their health plan with those whose pharmacy benefits are managed separately.

Evaluating Case Management Referral Patterns: Insights From an Enhanced Utilization Management Program 

This study examines how often requests for high-cost therapies are referred to case management within an enhanced utilization management program and identifies which patients might benefit most from additional support. 

Real-World Assessment of Cost and Utilization Trends of Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Antibody Therapy Among Different Sites of Care 

This study examines how often chimeric antigen receptor T-cell (CAR T) therapies and bispecific T-cell engager (BiTE) antibody therapies are used and how much they cost when administered in different settings — such as hospitals, outpatient clinics, doctors’ offices and at home. 

Real-World 1-Year Persistence to Glucagon-like Peptide-1 Receptor Agonists by Indication Among Commercially Insured Members Without Diabetes 

This study examines how long people without diabetes stayed on weight-loss GLP-1 medications over one year, based on a range of treated conditions. 

Real-World Patterns of On-Demand Utilization Following Initiation of Long-Term Prophylaxis in Hereditary Angioedema 

This study examines real-world use and cost for on-demand and long-term preventative therapies in patients with hereditary angioedema (HAE) — a rare, genetic immune system disorder that may cause swelling in the face, throat, limbs and abdomen. 

Reducing Pharmacy Costs Associated With the Proton Pump Inhibitor and Belumosudil Drug Interaction Through a Managed Care Pharmacist-to-Prescriber Telephonic Outreach Program 

This study evaluates a new HighTouchRx® intervention strategy in which managed care pharmacists contacted prescribers to address a drug interaction between belumosudil and proton pump inhibitors, which can lead to unnecessary medication costs.

Resident research posters

Impact of Social Determinants of Health on Biologic Utilization and Spending in Crohn’s Disease 

This study explores the relationship between social and economic factors and biologic medication choice and cost of treatment in individuals with Crohn’s disease.

Real-World Outcomes of Tepezza in Thyroid Eye Disease: Analyzing Treatment Persistence, Relapse, and Cost of Care

This study examines how individuals with thyroid eye disease adhered to teprotumumab treatment and how the therapy affected health outcomes and costs.